Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff

Core Viewpoint - Hims & Hers (HIMS) has experienced a significant stock decline of 47.96% over the past month, yet analysts project an 84% upside potential, with an average target price of $29.96, raising questions about whether this represents a buying opportunity or a value trap [1]. Regulatory Impact - The stock selloff was triggered by an FDA crackdown on Hims' compounded weight-loss drugs, which raised concerns over quality and safety, leading to a 14.1% drop in shares after the announcement [1]. - A lawsuit from Novo Nordisk for patent infringement over compounded semaglutide forced Hims to cancel its Wegovy alternative, impacting its growth strategy in the GLP-1 weight loss market [1]. Analyst Sentiment - Despite the regulatory challenges, analysts remain optimistic, with 1 Strong Buy, 2 Buy, 10 Hold, and only 2 Sell or Strong Sell ratings among the 15 analysts covering the stock [1]. - The bullish outlook is based on Hims' potential to diversify beyond weight loss into new specialties while maintaining strong subscriber growth and cash generation [1]. Financial Performance - Hims reported Q3 revenue of $599 million, reflecting a 49% year-over-year growth, with subscriber numbers increasing by 21% year-over-year to 2.5 million [1]. - The company generated $148.7 million in operating cash flow in Q3, indicating strong underlying business fundamentals [1]. Management Confidence - CFO Oluyemi Okupe has been actively buying shares during the recent dip, acquiring shares at $5.01 and $11.53, signaling management's confidence in the company's long-term prospects [1]. - The company aims to resolve issues with Novo Nordisk to regain access to the branded GLP-1 market, which could enhance its growth trajectory [1]. Future Outlook - Analysts suggest that the bull case strengthens if Hims secures a partnership with Novo Nordisk and successfully diversifies its offerings to offset weight loss headwinds [1]. - The company is targeting over $1 billion in annual revenue for its Hers brand by 2026, indicating ambitious growth plans [1].